- Tous > Medicine Information and Evidence for Policy > Medicines Policy
- Tous > Medicine Access and Rational Use > Financing
- Tous > Medicine Access and Rational Use > Pricing
- Tous > Quality and Safety: Medicines > Quality Assurance
- Tous > Quality and Safety: Medicines > Regulatory Support
- Tous > Public Health, Innovation, Intellectual Property and Trade > Intellectual Property (IP) and Trade
- Tous > Public Health, Innovation, Intellectual Property and Trade > Research and Development (R&D) - Innovation and Financing
- Mots-clés > affordable prices
- Mots-clés > innovation and intellectual property
- Mots-clés > The Lancet Commission on Essential Medicines Policies
- Mots-clés > new medicines
- Mots-clés > pharmaceutical industry social responsibility
- Mots-clés > pharmaceutical research and development (R&D)
- Mots-clés > policy - priority issues
- Mots-clés > prices / pricing policy
- Mots-clés > Sustainable Development Goals (SDGs)
- Mots-clés > universal health coverage (UHC)
(2016; 3 pages)
The Lancet: http://www.thelancet.com/commissions/essential-medicines
The report on essential medicines for universal health coverage (UHC) by the Lancet Commission on Essential Medicines Policies provides a timely contribution to discussions about how improving access to medicines can help achieve UHC. Nobody would dispute the need for improvements in both innovation of health-care technology and access to it, and there is much in the report with which I agree.
Improving access to medicines for patients across the world is a complex challenge. GlaxoSmithKline (GSK) continues to evolve its business model based on the twin drivers of innovation and access. We invest in R&D to discover and develop needed medicines and vaccines. We then seek a return on that investment, and measure our commercial success, by making those products accessible to as many people as possible. This includes flexible pricing and intellectual property policies which enable us to make an adequate return and continue to invest in research and development (R&D).
This approach means that GSK has led the Access to Medicines Index on the four occasions it has been compiled prior to the 2016 Index.